Join Alicia and Lizette as they speak with Dr. Rayne H. Rouce. Dr. Rouce is a pediatric hematologist and oncologist at Texas Children’s Cancer Center where she is a member of the Leukemia and Bone Marrow Transplant programs. Specifically, she works as part of a research program called The Center for Cell and Gene Therapy at Baylor College of Medicine, focused on translating targeted T-cell therapies from the bench to bedside, and has been involved in every aspect of CAR T-cell development for clinical use. On this episode, Dr. Rouce explains the process of chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy. She also explains the role of normal T cells, how re-engineered T cells are expected to perform after being reinfused into the patient, and the lifespan of these re-engineered T cells. Dr. Rouce shares her excitement not only for the future of CAR T-cell Therapy but also for the hope that this therapy provides to many patients and caregivers.
Podcast: Play in new window | Download
Subscribe: Spotify | Pandora | Blubrry | JioSaavn | Podchaser | More
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- CAR (chimeric antigen receptor) T-cell immunotherapy
- Clinical Trials
- Clinical Trial Support Center (CTSC)
Additional LLS Support Resources:
- CAR T-Cell Therapy Process
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts
- Information Specialists
- Free telephone/web patient programs
- Free booklets
- Financial support
- Caregiver support
- Support groups
Support for this episode provided by Celgene; Kite, A Gilead Company; and Novartis Oncology.